Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.255 -2.695 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.29 Bil PE Ratio: 0 PB Ratio: 1,065.02 GF Score: 78/100

Alnylam Pharmaceuticals Inc to Discuss Topline HELIOS-A Phase 3 Results of Vutrisiran - Conference Call Transcript

Jan 07, 2021 / 01:00PM GMT
Release Date Price: $139.4 (+9.91%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Alnylam Pharmaceuticals conference call to discuss top line HELIOS-A Phase III results. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speakers today, the company. Thank you. Please go ahead.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Akshay Vaishnaw, President of R&D; and Yvonne Greenstreet, President and Chief Operating Officer.

Also on the line and available for Q&A are Pushkal Garg, Chief Medical Officer; Tolga Tanguler, Chief Commercial Officer; and Rena Denoncourt, Senior Director, Program Leader for vutrisiran.

For those of you participating via conference call, the slides we made available

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot